Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05458674 · ClinicalTrials.gov registry record · Phase 2
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
A Phase 2 study of Breast Cancer and Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer, sponsored by Criterium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT05458674 is a Phase 2 study of Breast Cancer and Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer that is actively recruiting participants, run by Criterium. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05458674, a Phase 2 study of Breast Cancer and Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer, is actively recruiting participants, sponsored by Criterium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Eribulin
- DRUG Tucatinib
Study Locations (6)
Washington
- Swedish Cancer Institute - Issaquah
- Cancer Care Northwest - Spokane Valley
Colorado
- University of Colorado - Aurora
District of Columbia
- George Washington Medical Faculty Associates - Washington D.C.
New Mexico
- New Mexico Cancer Care Alliance - Albuquerque
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05458674
The ClinicalTrials.gov registry entry for NCT05458674 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.
NCT05458674 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Washington, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05458674 about?
NCT05458674 is a clinical study titled "Tucatinib+Trastuzumab+Eribulin in HER2+ MBC". The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, t...
What is the current status of trial NCT05458674?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-01-30. Estimated completion is 2027-08-01.
What conditions does trial NCT05458674 study?
This clinical trial studies the following conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer.
What interventions are being tested in trial NCT05458674?
The interventions under investigation include: Trastuzumab (DRUG), Eribulin (DRUG), Tucatinib (DRUG).
Who is sponsoring clinical trial NCT05458674?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05458674 being conducted?
This trial has 6 study locations across Colorado, District of Columbia, New Mexico, Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Breast Cancer
All registered trials for this condition
Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.